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Abstract 
Objectives: Determine the feasibility of recruiting and retaining patients recently diagnosed 
with thoracic cancer to a trial of short-term integrated rehabilitation; evaluate uptake of 
theoretically informed components targeting physical function, symptom self-management 
and participation; estimate sample size requirements for an efficacy trial. 
Design: Parallel group randomised controlled feasibility trial   
Setting: Three United Kingdom hospitals 
Participants: Patients ≤8 weeks of thoracic cancer diagnosis, Eastern Cooperative 
Oncology Group Performance Status 0–3, any cancer stage and treatment plan. 
Interventions: Participants randomly allocated (1:1) to short-term integrated rehabilitation 
and standard care or standard care alone over 30 days. 
Main measures: Primary: participant recruitment and retention, targeting ≥30% of eligible 
patients enrolling and ≥50% of participants reporting outcomes at 30 days. Secondary: 
intervention fidelity; missing data and performance of outcome measures for self-efficacy, 
symptoms, physical activity and health-related quality of life. 
Results: Of 159 eligible patients approached, 54 (34%) were recruited. 44 (82%) and 39 
(72%) participants reported outcomes at 30 and 60 days. Intervention fidelity was high. 
Rehabilitation was delivered across 3 (1-3) sessions over 32 (22-45) days (median(range)). 
Changes in clinical outcomes were modest but most apparent at 60 days for health-related 
quality of life: Functional Assessment of Cancer Therapy Lung Cancer score median [IQR] 
change 9.7 (-12.0-16.0) rehabilitation versus 2.3 (-15.0-14.5) standard care. 
Conclusion: A trial to examine efficacy of short-term integrated rehabilitation for people 
newly diagnosed with thoracic cancer is feasible. A sample of 336 participants could detect a 
meaningful effect on health-related quality of life as the primary outcome. 
Keywords: Feasibility Trial, Lung cancer, Mesothelioma, Rehabilitation, Randomised 
Controlled Trial, Thoracic Cancer 
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Introduction 
Worldwide, more people are diagnosed with lung  cancer than any other cancer [1] and the 
incidence of pleural mesothelioma continues to rise.[2] The prevalence of distressing and 
disabling symptoms in these thoracic cancers is high.[3, 4] Most people are diagnosed with 
advanced disease[1, 2] but strive to maintain normality in daily life.[5] Needs based cancer 
rehabilitation is recommended from diagnosis to reduce the impact of cancer and it’s 
treatment on functional well-being and to promote independence.[6] However, many people 
face difficulties accessing rehabilitation due to poor service provision, lack of clinician 
recognition of functional need [6] and/or negative views of rehabilitation.[7] Although 
traditional exercise-based interventions are safe and potentially effective in this population, 
rates of uptake and completion in supervised programmes are generally low.[8, 9] Symptom 
management interventions tend to be reactive, targeting patients with well-established 
symptoms.[10] Individualised pro-active rehabilitation programmes to minimise the impact of 
thoracic cancer on participation in daily life are lacking. To overcome some of these issues, 
we have developed a model of short-term integrated rehabilitation drawing on theories of 
illness,[11, 12] rehabilitation[13] and behaviour change.[14] Rehabilitation processes, 
components and outcomes were identified via systematic review [15] and focus groups with 
patients, carers and healthcare professionals.[16]  A manual was produced to support 
delivery of the intervention by a trained rehabilitation practitioner, (e.g. physiotherapist, 
occupational therapist or dietitian). Short-term integrated rehabilitation aims to support 
people to self-manage symptoms and immediate functional needs. It also aims to reduce 
sedentary time to minimise the onset of physical deconditioning. Strategies include 
maintaining or improving physical activity levels, fitness and participation in daily activities 
during cancer treatment and beyond. 
Before testing the efficacy of short-term integrated rehabilitation in a large-scale trial, we 
have undertaken this formal feasibility study. We aimed to: (1) determine the feasibility of 
recruiting and retaining people with thoracic cancer to a trial of short-term integrated 
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rehabilitation delivered in the period following diagnosis; (2) to evaluate uptake of 
theoretically informed, individually tailored intervention components and (3) obtain data on 
the acceptability of selected outcome measures and (4) estimate sample size requirements 
for an efficacy trial.  
Methods 
A multi-centre randomised controlled feasibility trial comparing the short-term integrated 
rehabilitation service plus standard care to standard care took place between February 2018 
and April 2019. The protocol was pre-registered (ISRCTN 92666109). Ethical approved was 
granted by the London South East Research Ethics Committee (Ref 17/LO/1871). Reporting 
follows the CONSORT guidelines and the Template for Intervention Description and 
Replication (TIDieR) checklist. No changes were made to the design or methods following 
trial commencement. 
Participants were recruited from thoracic oncology, palliative care and respiratory clinics 
across three UK hospitals, two in London and one in Nottingham. Eligible participants were 
adults, within 8 weeks of a clinical or histological diagnosis of primary lung cancer (stage I-
IV) or pleural mesothelioma (local or extensive), Eastern Cooperative Oncology Group 
Performance Status of 0-3 (appendix 1)[17] and the ability to respond to questions in written 
English (or availability of translators to support this). People already receiving specialist 
rehabilitation, or who had a co-existing progressive neurological condition (e.g. motor 
neurone disease), Eastern Cooperative Oncology Group Performance Status 4, not able to 
complete questionnaires due to cognitive impairment, or with a physician-estimated 
prognosis of <1 month were excluded. All participants gave written informed consent in 
accordance with Good Clinical Practice and the Declaration of Helsinki.  
Following baseline assessment, conducted in hospital out-patients, in-patients or home 
settings, participants were randomly allocated (1:1 at the individual level) using an 
independent web-based randomisation system at the King’s Clinical Trials Unit, London, UK. 
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A minimisation algorithm was used to maintain balance in both the trial groups for 
recruitment site, performance status (0-1 or 2-3) and disease stage (I-II or III-IV). Following 
randomisation, the Clinical Trials Unit informed trial staff via secure email. Research nurses, 
who arranged outcome assessments using self-report mailed questionnaires, were informed 
of trial entry but not group allocation. Due to the nature of the intervention, it was not 
possible to maintain allocation blinding for participants and trial physiotherapists (JB, MM, 
LF, ED). The trial statistician (WG) was also blind to group allocation. 
All participants received standard care provided by their hospital for their condition. This 
included surgical, oncology and supportive and palliative care services. No rehabilitation was 
routinely provided at two sites. One London site provided multi-professional out-patient 
based specialist rehabilitation for patients attending oncology follow-up clinics with functional 
needs identified following screening. We planned to recruit participants who were not 
scheduled or able to attend these clinics within eight weeks of diagnosis. 
Participants allocated to short-term integrated rehabilitation (Figure 1) were offered up to 
three sessions with a rehabilitation practitioner (physiotherapists) over six weeks (trained by 
JB). As indicated during model development,[16] a flexible delivery approach was used with 
appointments lasting up to one hour, in the hospital or home setting, and scheduled 
according to participant preference. Where possible, first appointments were face to face. 
Subsequent appointments were face to face or by telephone according to practical 
considerations and participant preference. The intervention used a psychologically-informed 
approach[18] to identify immediate functional priorities and concerns, illness understandings 
and future expectations relating to functional well-being. A intervention manual (available 
here) was used to standardise change processes[19] but was unscripted to enable tailoring 
and adaptation of intervention components to meet the expected variation in function related 
needs. Intervention components were selected as indicated and included personalised 
information about the impact of thoracic cancer on function and goal planning for symptom 
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prevention and/or self-management, graded physical activity, home-based exercise and 
participation and performance in activities of daily living. 
Intervention components were delivered using behaviour change techniques[14] to support 
receipt and enactment. Information booklets, handheld fans and walking aids were offered 
and provided to support delivery of intervention components. An individual goal orientated 
action plan, developed in consultation with each participant and held by them, was reviewed 
and updated at each session to support enactment. Participants were sign-posted to local 
hospital, community-based, hospice and charitable services (i.e. local cancer support 
organisations) as indicated in the manual and where available for on-going support. Those 
wanting to pursue supervised exercise training to improve fitness were sign-posted to local 
exercise services. At discharge, a letter summarising the participant’s rehabilitation 
intervention and discharge action plan was sent to the participant and copied to their multi-
professional team for follow-up and onward referrals. 
Our primary feasibility outcomes were rates of participant enrolment and retention. 
Feasibility endpoints, established a priori, were defined as ≥30% of eligible patients 
consenting to the trial and ≥50% of enrolled participants completing clinical outcome 
measures at 30 days. Secondary feasibility objectives were number of rehabilitation contacts 
delivered over 30 days, fidelity of service delivery, including use of intervention components 
and onwards referral to local rehabilitation services, and missing data on clinical outcome 
measures at 30 and 60 days. Participant self-reported experiences were assessed by self-
reported questionnaire comprising four items on trial processes from a national experience 
survey[20] and ten items on satisfaction with the intervention from the Functional 
Assessment of Chronic Illness Therapy Treatment/ Patient Satisfaction (version 4)[21]. Free 
text comments were also invited.  
Clinical outcomes were assessed at baseline, 30 days and 60 days following randomisation 
via self-reported postal questionnaire. Higher scores are better for all measures except the 
Integrated Palliative Outcome Scale and the Client Services Receipt Inventory. Symptoms 
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and concerns were measured by the Integrated Palliative Outcome Scale (17 items, total 
score 0-68);[22] physical activity level by the Physical Activity Scale for the Elderly (28 items, 
0-400);[23] health-related quality of life measured by the Functional Assessment of Cancer 
Therapy-Lung (total 34 item, 0-136; Functional Assessment of Cancer Therapy-Trial 
Outcome Index (21 items, 0-84); Functional Assessment of Cancer Therapy-lung cancer 
subscale 7 items, (0-28);[24] EQ-5D-5L (index values -1 to 1, EQ-VAS 0-100);[25] and 
confidence measured by the Self-Efficacy Measure for Chronic Disease (6 items, 0-60).[26] 
The Client Services Receipt Inventory[27] was used to measure resource use relating to 
hospital and community services, including social care, informal care and equipment 
provision. No changes were made to outcome assessments during the trial. 
As this trial was designed to assess the feasibility of testing the short-term integrated 
rehabilitation intervention, a formal power calculation around an estimated effect size on 
clinical outcome was not appropriate. Sample sizes of 24-60 participants have been 
recommended for feasibility studies.[28, 29] We took a conservative approach and aimed to 
recruit up to 60 participants which would allow us to estimate feasibility parameters and 
outcomes with sufficient precision to inform a future sample size calculation. 
Statistical analysis 
Data were analysed using SPSS (version 24, Chicago, IL, USA) under intention-to-treat 
principles. Feasibility outcomes and baseline demographics were summarised using 
descriptive statistics. Data on treatment fidelity in the intervention group were extracted from 
case report forms using the Behaviour Change Technique Taxonomy (version 1)[30] by a 
trained member of the research team (JB). Treatment receipt was defined as the participant 
receiving 1-3 rehabilitation sessions comprising symptom management ± physical activity or 
exercise ± task performance and participation interventions. Reasons for withdrawal or loss-
to-follow up from the trial were summarised and classified by Attrition Due to Death (ADD), 
Attrition Due to Illness (ADI) or Attrition at Random (AaR).[31] The proportions of participants 
missing each variable were summarised by group at each time point. All serious adverse 
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events (SAE) and adverse events (AE) relating to the intervention were summarised. This 
trial did not aim to evaluate effectiveness, therefore clinical outcomes were described by trial 
group at baseline and both follow-up time points, using standard descriptive statistics, 
without significance testing.  
Results 
Figure 2 shows participant flow through the trial. Between February 2018 and January 2019, 
374 patients were screened of whom 159 (42%) were eligible and 54 (34%) were enrolled. 
An overall recruitment rate of 4.5 participants per month was achieved with 1-2 accruals per 
month at each site. Barriers to additional recruitment included personal absences in the 
clinical and research teams and changes to site working practices, e.g. availability of lung 
cancer nurse specialists and allocation of space in oncology clinics. Following randomisation 
82% and 72% of participants returned follow-up outcome measures at 30 and 60 days 
respectively. Attrition was comparable across both groups. In the rehabilitation group, one 
participant withdrew before receiving the intervention due to rapidly progressing disease, 
and one was lost to follow-up after receiving one rehabilitation contact. In the standard care 
group two participants were lost to follow-up, and one withdrew from the trial. Postal 
questionnaires from four participants who remained in the trial (three rehabilitation group, 
one standard care group) were not received at 30 days. 
Participants had a median (range) age of 67 (44-85) years and 35 (65%) were men. Most 
were retired or not employed (32/54, 60%) though some were on sick leave (14/54, 27%) or 
still working (7/54, 14%). Less than one-quarter of participants lived alone. The majority 
37/54 (68%) had non-small cell lung cancer (NSCLC), though small cell lung cancer (SCLC), 
pleural mesothelioma and neuroendocrine tumours were represented. Thirty nine (72%) had 
stage III-IV disease (27 metastatic), of whom over half were scheduled for treatment with 
chemotherapy doublet combinations. Group allocation differences in mesothelioma 
diagnosis and disease stage were noted (Table 1). 
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Overall engagement with the rehabilitation intervention was high and it was delivered 
according to protocol (Table 2). Across the 26 participants allocated to the intervention group 
69 rehabilitation sessions were delivered with a median of 3 per participant. Twenty-one 
participants (84%) accessed all three rehabilitation sessions. Two-thirds of rehabilitation 
sessions were delivered face to face in the home; others occurred in hospital outpatient 
settings with a single session delivered on a hospital inpatient unit. The median duration of 
the first session was one hour and follow-up sessions, forty-five minutes. Two participants 
declined further sessions as they perceived no needs or were too busy with appointments, 
though both remained in the trial. 
Most participants engaged with all core intervention components; physical activity and 
exercise (24/25, 96%), symptom self-management (20/25, 80%), and task 
performance/participation (20/25, 80%). Interventions frequently accepted by participants 
were home-based exercise or physical activity programmes and self-management strategies 
for fatigue and breathlessness. Few participants reported current problems managing 
personal activities of daily living, though 20/25 (80%) and 16/25 (64%) were provided with 
strategies to support work/leisure or domestic activities respectively.  
Regarding use of behaviour change techniques,[14] ‘credible source’ and ‘information about 
health consequences’ were used to support intervention delivery in all participants 
(supplementary table 1). Behaviour change techniques relating to goal setting, action 
planning, feedback and self-monitoring, instruction, practice, and ‘verbal persuasion about 
capability’ were used with over three-quarters of participants. Strategies to reduce negative 
emotions supported intervention delivery and enactment of rehabilitation plans in 12/25 
(48%) participants. Nine interventions delivered (9/26, 36%) included ‘adding objects to the 
environment’ (handheld fans and assistive devices), though restructuring of the physical and 
social environment did not take place. Evaluation of participant enactment of rehabilitation 
plans was clearly documented in most follow up sessions.  
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No serious adverse events related to the intervention occurred. Two participants died 
following disease progressions and seven participants were admitted to hospital relating to 
disease and oncology treatments (disease progression n=3; sepsis, anaemia, pulmonary 
embolus, blocked stent, all n=1). Six intervention group participants reported transitional 
worsening of symptoms following exercise or walking activities, two reported delayed onset 
muscle soreness and one had a non-injurious fall from a bicycle.  
Rates of missing data items in returned questionnaires were low (supplementary table 2). 
Postal questionnaires from four participants who remained in the trial were not received at 
30 days. One participant engaged with the intervention, but outcome measures were not 
received.  
The item most frequently missed was Functional Assessment of Cancer Therapy-Lung item 
‘satisfaction with sex life’ (50%) and items in the Client Services Receipt Inventory relating to 
personal care (45%) and rehabilitation services (physiotherapy, occupational therapy and 
dietitian, 27-36%). The Physical Activity Scale for the Elderly questionnaire allocates a score 
of -1 to a weighted domain containing missing items so all obtained questionnaires were 
scored despite missing items in 6 (14%) and 5 (13%) questionnaires at 30 and 60 days 
respectively. 
Trial participation satisfaction was high in both groups (median 12) with a wider range of 
scores in the standard care group. Free text comments from fifteen participants described 
mostly positive experiences. Two intervention and three standard care group participants felt 
the questionnaires were too long or hard to fill in. Two standard care participants were 
unhappy with group allocation. Satisfaction with the rehabilitation intervention was also high 
with a maximum obtainable median score of 27 (range 23-27). Fourteen participants 
completed free text comments describing the impact of the intervention and the involvement 
of family members during intervention delivery. Participants valued the practical advice and 
face to face contact, reporting that the experience had been ‘helpful’, ‘useful,’ ‘educational’ 
and ‘empowering’. Two would have preferred more sessions. Nine commented that they 
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valued involvement of a family member while three reported feeling able to talk more freely 
without family member present. 
Table 3 displays change in outcomes at 30 and 60 days. Baseline scores (Table 1) were 
comparable across both groups  for all measures except the Physical Activity Scale for the 
Elderly, which indicated the rehabilitation group were more physically active. Overall, 
participants were generally sedentary, reported moderate symptom burden (Integrated 
Palliative Outcome Scale, median [IQR] score19 [13 - 28]), and reported having confidence 
to manage their disease (Self-Efficacy Measure for Chronic Disease 6.7 [5.0 - 8.2]). Client 
Services Receipt Inventory data indicate that about half of all participants were receiving 
support with personal care. 
Changes over time were modest at both time points and a large degree of heterogeneity was 
evident (Table 3). Change was most apparent for physical activity level and health-related 
quality of life. Changes in Physical Activity Scale for the Elderly scores were small in both 
groups at 30 and 60 days, with slightly higher scores in the standard care group at 60 days 
(median [IQR] 1.6 [-10.7 - 50.6]) and worsening scores for rehabilitation at 60 days (-15.5 [-
50.8 - 38.9]). This contrasted with health-related quality of life scores which favoured the 
rehabilitation group. At 60 days, Functional Assessment of Cancer Therapy-Lung scores 
improved by a median of 9.7 [-12.0 - 16.0] compared to 2.3 [-15.0 - 14.5] with standard care. 
Similarly, FACT-Trial Outcome Index rehabilitation group scores improved by 6 [-12 - 15.0] 
as compared with 4.5 [-13.0 - 9.8] with standard care. Despite comparable reductions in the 
EQ-5D utility index in both groups, a small worsening in EQ-VAS median score was 
observed in the standard care group at 30 and 60 days (-2.5 [-20.0 - 5.0] and -6.5 [-13.8 - 
8.8]) as compared to no change then a small improvement (0 [0 - 10] and 5.0 [-17.5 - 24.8]) 
in the rehabilitation group. Symptoms reduced by a small amount at 30 days in both groups 
though by 60 days, scores had improved by a median [IQR] of -4.5 [ -12.5 - 6.0] in the 
rehabilitation group and -2.1 [-8.0 - 4.0] in the standard care group. 
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Discussion 
This trial has found that it is feasible to recruit and retain people newly diagnosed with 
thoracic cancer to a randomised controlled trial of short-term integrated rehabilitation versus 
standard care. Data relating to recruitment, retention and engagement with the rehabilitation 
intervention suggest the trial was well designed and implemented, and that this model of 
rehabilitation is acceptable and accessible for patients across a range of clinical and 
demographic characteristics. The primary feasibility outcomes were achieved: 34% of 
eligible participants were recruited and 82% were retained on trial for 30 days. 
Low baseline levels of physical activity indicate that the sample was representative of the 
population.[32] Engagement with the rehabilitation intervention and intervention fidelity were 
high. More than 96% of participants allocated to receive rehabilitation accessed at least one 
session of rehabilitation and more than 75% accessed each of the three core intervention 
components. Low levels of missing data in the clinical outcomes suggest that measures 
were acceptable to participants and have potential to be used in a future trial (see 
supplementary material). However unclear or missing data in the self-reported Client 
Services Receipt Inventory domains relating to physiotherapy, occupational therapy, in-
patient and out-patient rehabilitation meant it was difficult to quantify and evaluate access to 
rehabilitation services. Participants rarely completed number of contacts, duration of 
intervention or provided information to enable assessment of contamination. 
The trial did not aim to test effectiveness and inferential statistical tests were not conducted. 
It is however of interest that changes in median scores at day 30 and day 60 were higher in 
the rehabilitation group for all measures except EQ-5D-5L index scores and Physical Activity 
Scale for the Elderly. Modest changes observed in clinical outcome measures were larger in 
Functional Assessment of Cancer Therapy-Lung and EQ VAS. Changes in Physical Activity 
Scale for the Elderly scores were less than the minimally important difference for this 
population.[23] During development work, confidence was identified as a key modifiable 
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factor regardless of participant disease stage or performance status,[16] however minimal 
changes were observed in Self-Efficacy Measure for Chronic Disease scores. 
This theory-based model of short-term integrated rehabilitation differs from other 
rehabilitation interventions tested in people with thoracic cancer in key areas. It brings 
together strategies to optimise physical function, symptom self-management and 
participation in valued daily activities. Rehabilitation interventions delivered following 
diagnosis have the potential to minimise the impact of disease and treatment-related 
symptoms, such as breathlessness and fatigue, on symptom experience, functional 
independence in activities of daily living and quality of life.[6] The majority of research 
studies focus on exercise interventions for people on curative treatment pathways.[9] 
Exercise was prescribed during short-term integrated rehabilitation when participants were 
willing to engage, but if not, other rehabilitation components, including preventive strategies 
were used to optimise physical activity levels and to minimise the onset of symptoms 
developing alongside physical deconditioning. Holistic breathlessness services improve 
distress relating to refractory breathlessness[10] but have not yet been tested in people 
mainly limited by exertional breathlessness, as reported by participants in this trial.  
The trial has several strengths. Firstly, we were able to recruit and retain participants with a 
diverse range of demographic characteristics, disease stage and comorbidities on all 
thoracic cancer treatment pathways. The recruitment and retention rates indicate that the 
trial design and research personnel were able to address some of the barriers influencing 
participation in rehabilitation and exercise-based interventions in people with thoracic 
cancer.[16, 33] Few participants declined for reasons relating to rehabilitation being a burden 
or unnecessary as found in a large mixed methods study where receptiveness to 
rehabilitation was low across all participants with mild to severe levels of disability.[7] Most 
participants in this trial declined as they had too much going on or were not interested, 
findings congruent with previous studies. Although continuing with normal life following 
diagnosis is important to patients,[5] it cannot be assumed that they will want to have any 
14 
 
functional concerns met by health providers. Brown et al. found that people with lung cancer 
may prefer to access functional support from their own family.[34] 
The trial has addressed uncertainties surrounding the delivery of rehabilitation interventions 
at a time when patients are coming to terms emotionally with their new life situation while 
undergoing a busy and potentially arduous oncology treatment schedule.[35]  As prioritised 
in trial development work,[15, 16] we were able to deliver and test an inclusive, flexible and 
tailored model of rehabilitation to address the heterogeneity of functional need. The model of 
short-term integrated rehabilitation echoes effective and valued components of holistic 
breathlessness services. It was delivered by an expert provider, integrated with busy 
treatment schedules and focused on participants’ immediate functional concerns and 
priorities.[10] 
The comparability of groups at baseline indicates that the randomisation system and 
minimisation categories worked well. However, all mesothelioma participants were 
randomised to receive standard care. In view of the changing treatment options and 
outcomes dependent on histological diagnosis, minimising for diagnosis should be 
considered in a larger trial. Although the rehabilitation model was designed to be inclusive 
and accessible for participants with an Eastern Cooperative Oncology Group Performance 
Status of 0-3, it is disappointing that few disabled participants were recruited with most 
participants having an Eastern Cooperative Oncology Group Performance Status 0-1. The 
performance status of those declining to participate was not always available, so it is not 
known if participants with a performance status of 2-3 were approached and declined or if 
they were not identified during screening. Recruitment strategies in future trials need to 
consider how this group may be better represented in the sample, for example, asking 
people with a performance status of 2-3 to review trial recruitment materials and processes. 
The constraints of delivering the intervention in a feasibility trial meant that integration with 
other oncology services was harder to achieve than was anticipated. To optimise 
accessibility and to reduce participant burden, we aimed to deliver the intervention alongside 
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scheduled hospital appointments. This presented challenges as intervention providers were 
based off site and scheduled hospital appointments were frequently booked or changed at 
short notice. Attendance at thoracic cancer multi-professional team meetings across three 
sites was not possible with the available trial personal. Changes in working practices at two 
hospital sites meant clinic space was not always available. In addition, some participants 
had gaps between appointments longer than the 6-week intervention delivery period. 
Delivering the intervention in the hospital setting was more achievable when participants 
were attending for daily radiotherapy or weekly chemotherapy. Some participants treated 
with surgery lived too far for home visits and had no post-operative appointments within the 
trial period and were therefore unable to enrol in the trial. Other integration strategies were 
achieved. These included providing participants with a written rehabilitation plan which they 
were encouraged to share with other health care professionals involved in their care. A 
discharge letter summarising the intervention and rehabilitation plan was sent to each 
participant on discharge and copied to their oncologist and case-notes.  
The findings of this feasibility trial have implications for future research and clinical practice. 
High levels of participant retention, intervention fidelity and rates of data completeness with 
few non-serious adverse events suggest that the trial processes, intervention and outcome 
measures were acceptable to participants. Training members of the usual health care team 
in screening for and delivering the intervention in a full trial should improve capacity to 
deliver the intervention alongside schedules appointments and reduce performance bias. 
The design of a full trial should consider how to reach participants with Eastern Cooperative 
Oncology Group Performance Status  2 to 3 and those living further away from the recruiting 
centres. 
Identifying a primary outcome for trials of rehabilitation interventions in this populations is 
challenging, limited in part by the availability of suitable measures.[36] The findings suggest 
that the more discrete measures (physical activity and confidence) were not relevant to all 
participants. The inclusive approach to eligibility, heterogeneity of the population, bi-
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directionality of functional trajectories, mean that the health-related quality of life measure is 
more able to capture the impact of the short-term integrated rehabilitation intervention and 
should be considered as primary outcomes for a future trial. This is in line with the findings of 
a recent trial of home-based rehabilitation for people with inoperable lung cancer. Edbrooke 
et al. observed significant improvements in health related quality of life and symptom levels 
with no changes in the primary outcome, physical function as measured by the 6 minute 
walking test.[36]  
An estimated sample size for a future trial was calculated based on the observed changes in 
Functional Assessment of Cancer Therapy-Lung. Assuming a difference of 6 points, which is 
similar to the point estimate of effect we observed, and allowing for 25% attrition, 336 
participants would be required to reliably detect this difference (80% power, p=0.05) in an 
efficacy trial. 
If shown to be effective, this model of rehabilitation would provide proactive support around 
the time of diagnosis for people with thoracic cancer. It would provide a route to 
consecutively screen patients and shift the focus of rehabilitation towards self-management 
and maintaining rather than regaining function. Further, it can contribute to the integration of 
rehabilitation into oncology services. 
This study has found that it is feasible to deliver and test a new, theory-based model of 
rehabilitation that differs from exercise interventions typically tested in people newly 
diagnosed with thoracic cancer. It is an inclusive intervention which addresses the 
heterogeneity of functional need and barriers to rehabilitation observed in people newly 
diagnosed with thoracic cancer. We were able to deliver and test the new model in a 
feasibility trial, and efficacy testing is now warranted. 
Clinical Messages 
 It is feasible to deliver and test short-term integrated rehabilitation for thoracic cancer 
in a randomised controlled trial in the period following diagnosis  
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 A sample size of 336 would be needed to detect a clinically important difference in 
health-related quality of life in an efficacy trial  
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Figure 1 Conceptual Model of Short Term Integrated Rehabilitation for Thoracic Cancer 
(adapted from Wade 2005[13]) 
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Figure 2 CONSORT flow diagram  
*3 participants in the intervention group and one in the standard care group who did not 
return data at 30 days, did return data at 60 days. ECOG PS = Eastern Cooperative 
Oncology Group Performance Status. 
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Table 1 Participant baseline characteristics 
Variables  Total 
N=54 
Standard Care 
N=28 
Rehabilitation 
N=26 
Site: 
 
1. 
2. 
3. 
25 (46) 
18 (33) 
11 (20) 
13 
9 
6 
12 
9 
5 
Age in  years (range)  67 (44-85) 67 (44-85) 66 (46-83) 
Gender 
 
Women 
Men 
19 (35) 
35 (65) 
8 
20 
11 
15 
Ethnicity 
 
White British 
Caribbean/Indian/Bangladeshi/ 
African 
Other white 
42 (78) 
5 (9) 
7 (13) 
25 
1 
2 
17 
4 
5 
Diagnosis 
 
NSCLC (adeno) 
NSCLC (squamous) 
SCLC 
Pleural mesothelioma 
Neuroendocrine 
24 (44) 
13 (24) 
9 (17) 
5 (9) 
3 (6) 
10 
7 
5 
5 
1 
14 
6 
4 
0 
2 
Days from diagnosis (range)  44 (2-65) 43 (2-65) 44 (3-60) 
Disease by each stage  
 
I 
II-IIIa 
IIIb 
IV 
11 (20) 
12 (22) 
8 (15) 
23 (43) 
5 
7 
6 
10 
6 
5 
2 
13 
ECOG PS 0-1 
2-3 
47 (87) 
7 (13) 
24 
4 
23 
3 
Metastases 
 
None 
Local 
Distant 
27 (50) 
6 (11) 
21 (39) 
16 
3 
9 
11 
3 
12 
Comorbidities 
 
COPD/CVD 
Diabetes 
MSK/ Inflammatory arthritis 
18 (34) 
10 (19) 
18 (33) 
7 
4 
10 
11 
6 
8 
Smoking History 
 
Current 
Ex-smoker 
Never smoked 
Missing 
5 (9) 
40 (76) 
8 (15) 
1 (2) 
2 
23 
2 
1 
3 
17 
6 
0 
Lives with 
 
Alone 
Spouse/Partner 
Other family/ Other 
12 (22) 
31 (57) 
11 (21) 
4 
18 
6 
8 
13 
5 
Employment 
 
Employed 
Sick leave 
Retired/not employed 
7 (14) 
14 (27) 
31 (60) 
5 
4 
18 
2 
10 
13 
Self-reported previous 
physical activity 
Sedentary 
Mild 
Moderate 
Vigorous 
13 (24) 
27 (50) 
12 (22) 
2 (4) 
8 
12 
6 
2 
5 
15 
6 
0 
Anti-Cancer Treatment 
(commenced or planned) 
 
Surgery† 
Chemotherapy doublet 
Radical radiotherapy ± chemotherapy 
Palliative chemoradiotherapy 
Targeted therapy/immunotherapy‡ 
Palliative radiotherapy   
13 (24) 
22 (41) 
8(15) 
6 (11) 
4 (7) 
1 (2) 
4 
15 
5 
2 
1 
0 
8 
7 
3 
4 
3 
1 
Baseline Outcome Measure 
Scores 
IPOS  19.00 [1.03-28.0] 16.5 [13.0-27.8] 20.0 [12.8-28.3] 
 PASE 74.0 [42.9-117.4] 61.8 [30.9-105.7] 97.3 [52.2-170.9] 
 FACT-L 93.0 [79.4-104.3] 91.5 [80.6-105.8] 94.5 [76.0-104.0] 
 FACT-LCS 17.0 [14.0-23.0] 19.5 [14.0-23.8] 16.5 [13.8-20.8] 
 FACT-TOI 52.0 [44.75-63.25] 50.0 [45.3-62.8] 53.5 [39.8-62.8] 
 SEMCD 6.7 [5.0-8.2] 6.4 [5.1-8.5] 6.8 [5.0-8.0] 
 EQ-5D-5L Index Value 0.76 [0.65-0.84] 0.77 [0.6-0.8] 0.8 [0.65-0.9] 
 EQ VAS 67.5 [50.0-80.0] 70.0 [50.0-80.0] 62.5 [48.8-80.0] 
Baseline characteristics: values are number (percentage) or median (IQR). NSCLC = non-small cell lung cancer; SCLC= small 
cell lung cancer; ECOG =Eastern Cooperative Oncology Group; COPD = Chronic Obstructive Pulmonary Disease; CVD 
=Cardiovascular disease; MSK = musculo-skeletal disease. † includes n=2 surgery & chemotherapy ‡ includes n=1 
immunotherapy & chemotherapy. IPOS =Integrated Palliative Care Outcome Scale; PASE= Physical Activity Scale for the 
Elderly; FACT-L/TOI/LCS = Functional Assessment of Cancer Therapy- Lung/trial outcome index/lung cancer subscale; SEMCD 
= Self-Efficacy Measure for Chronic Disease 
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Table 2 Intervention Fidelity 
Intervention Variable   N (%)  
unless stated 
Rehabilitation providers oncology expertise a  
Band 7 physiotherapist level 4 
Band 8 physiotherapist level 3 
2 
1 
Uptake and mode of rehabilitation  
Days to first session (range, target <14) 7 (5-13) 
Days first to last session (range, target <42) 32 (22-45) 
Sessions received 
One 
Two 
Three 
 
25 (96)  
23 (88) 
21 (84) 
Duration of sessions in minutes (range) 
1st 
2nd  
3rd 
 
60 (60-80) 
48 (35-61) 
45 (33-60) 
Face to face 
Home 
Hospital outpatient clinic 
In-patients 
Telephone  
55 (80) 
37 (67) 
17 (31) 
1 (2) 
14 (20) 
Intervention procedures 
Symptom management strategies 
Physical activity / fitness strategies (including exercise) 
Task performance / participation strategies 
20 (80) 
24 (96) 
20 (80) 
Equipment provision 
Handheld fan 
Walking aids 
Perching stool 
 
7(28) 
2(8) 
1(4) 
Rehabilitation plan  
Agreed and document provided to participant 
Shared with oncologist / multi-disciplinary team 
 
25 (100) 
24 (96) 
Signposting 
Cancer centre rehabilitation  
Community based exercise‡ 
Community based rehabilitation 
Hospice rehabilitation  
Palliative care team 
 
13 (52) 
5 (20) 
3 (12) 
3 (12) 
1 (4) 
Behaviour Change Techniquesb  
Goals and planning 
Feedback and monitoring  
Social support 
Shaping knowledge 
Natural consequences 
Comparison of behaviours 
Associations 
Repetition and substitution 
Comparison of outcomes  
Regulation 
Antecedents 
Identity/Self Belief 
24 (96) 
23 (92) 
17 (68) 
24 (96) 
25 (100) 
23 (92) 
11 (44) 
20 (80) 
25 (100) 
12 (48) 
9 (36) 
21 (84) 
aBased on ‘Improving supportive and palliative care for adults with cancer. The manual’. NICE 2004.[37] Pg.144-145. 
‡includes yoga, Pilates, local cancer support organisations and walking groups. 
b categorised and ordered according to the Behaviour Change Techniques Taxonomy version 1 (Michie 2014) 
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Table 3 Participant Self-Reported Outcome Data at 30 and 60 days: median (IQR) 
Group  Standard Care   Rehabilitation 
 
 30 days 
N=28 
Change from 
baseline 
60 days 
N=28 
Change from 
baseline 
 30 days 
N=26 
Change from 
baseline 
60 days 
N=26 
Change from 
baseline 
Outcome*           
IPOS total 
 
 21.0 [12-25] -2.1 [-5.0-1.0] 18.0 [6.8  -25.0] -2.1 [-8.0-4.0]  19 [13.5-26.5] -0.5 [-9.0-5.5] 17.0 [8.8 -23.0] -4.5 [-12.5-6.0] 
 
PASE total  
 
 74.3 [32.6-111.6] 
 
2.0 [-18.5-37.5] 105.7 [62.9-130.8] 1.6 [-10.7-50.6]  75.9 [42.3-153.7] -4.5[-27.8-32.9] 
 
92.9 [38.9-170.8] -15.5 [-50.8-38.9] 
 
FACT-L 
 
 93.5 [82.8-105.7] 1.3 [ -9.7-13.7] 96.0 [78.8-111.9] 2.3[-15.0-14.5]  99.0 [75.3-105.0] 0.0[-8.0-11.0] 97.0 [80.0-103.8] 9.7 [-12.0-16.0] 
 
FACT-LCS  
 
 18.0 [16.3-22.3] 0 [-3.0-4.0] 19.0 [14.8-23.8] 1.5 [-5.3-5.0]  19.0 [17.0-23.0] 2.0 [-0.8-5.5] 
 
19.0 [17.0-22.0] 3.0 [-4.0-7.0] 
FACT-TOI  50.1 [39.3-57.8] -1.0 [-10.1-4.5] 53.0 [43.5-66.0] 4.5 [-13.0-9.8]  56.5 [47.0-65.0] 0.0 [-5.0-7.0] 56.2 [46.0-60.0] 6.0 [-12.0-15.0] 
 
SEMCD  
 
 5.3 [3.7-8.5] -0.8 [-1.9-0.7] 6.3 [4.8-8.3] 0.0 [-0.8-0.7]  6.2 [4.8-8.5] 0.3 [-0.8-1.5] 
 
7.0 [5.8-8.3] 0.2 [-1.5-1.5] 
 
EQ-5D-5L Index score  0.65 [0.4-0.8] -0.09 [-0.23-0.05] 
 
0.67 [0.6-0.9] -0.04 [-0.18-0.15]  0.7 [0.40-0.9] -0.03 [-0.24-0.15] 
 
0.7 [0.64-0.8] -0.02 [-0.28-0.07] 
EQ-5D-5L VAS  60.0 [40.0-78.8] -2.5 [-20.0-5.0] 
 
65.0 [50.0-80.0] -6.5 [-13.8-8.8]  65.0 [52.5-83.8] 0 [0-10.0] 70.0 [58.8-77.5] 5.0 [-17.5-24.8] 
 
Trial satisfaction   12.0 [9.0-14.0] n/a n/a n/a  12.0 [9.5-14.8] n/a n/a n/a 
FACIT-PS-TS 
Overall satisfaction  
 n/a n/a n/a n/a  27 [27-27] 
4 [3-4] 
n/a n/a n/a 
*Higher is better for all measures except IPOS and CSRI where lower scores are better. Median [25th -75th percentile].  
IPOS =Integrated Palliative Care Outcome Scale; PASE= Physical Activity Scale for the Elderly; FACT-L/TOI/LCS = Functional Assessment of Cancer Therapy- Lung/trial outcome index/lung cancer subscale; 
SEMCD = Self-Efficacy Measure for Chronic Disease; FACIT-PS-TS = Functional Assessment of chronic illness therapy treatment/ patient satisfaction. †n=1 participant with 30 day measures lost in mail, 
completed trial satisfaction at 60 days 
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Appendix 1 
Grade  Eastern Cooperative Oncology Group Performance Status 
0  Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g. light housework, office work 
2 Ambulatory and capable of self-care but unable to carry out work activities; up 
and about for more than 50% of waking hours 
3  Capable of limited self-care, confined to bed or chair for more than 50% of 
waking hours 
4 Completely disabled, cannot carry on any self-care, totally confined to bed or 
chair
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Supplementary Table 1 Details of rehabilitation strategies and behaviour change techniques 
Rehabilitation Strategies N (%) 
Symptom management strategies: Breathlessness 
   Fatigue 
   Pain 
   Nutrition/appetite 
   Sleep 
Leaflet 
 
Physical activity/fitness strategies: Physical activity strategies 
  Exercise prescription 
Leaflet 
 
Task performance/participation Personal ADLa 
strategies:   Domestic ADL 
   Instrumental ADL 
15 (60) 
17 (68) 
8 (32) 
8 (32) 
7 (28) 
11 (44) 
 
24 (96) 
22 (88) 
20 (80) 
 
3 (12) 
16 (64) 
20 (80) 
Behaviour Change Techniques (BCTs)b  
BCT Group  BCT label 
Goals and planning  Goal setting behaviour 
 Problem solving 
 Goal-setting outcome 
 Action planning 
 Review behaviour 
    Review outcome goals 
 
Feedback and monitoring   Feedback on behaviour 
  Self-monitoring of behaviour 
  Self-monitoring of outcomes of behaviour 
 
Social support   Unspecified 
  Practical 
  Emotional 
 
Shaping knowledge  Instruction on how to perform behaviour 
  Information about antecedents of behaviour 
  Behavioural experiments 
 
Natural consequences  Information about health consequences 
  Monitoring of emotional consequences 
  Information about emotional consequences  
 
Comparison of behaviour  Demonstration of behaviour 
 
Associations   Prompts and cues 
 
Repetition and substitution  Behavioural practice 
  Habits formation 
  Graded tasks 
 
Comparison of outcomes  Credible Source 
  Comparative imagining of future outcomes 
 
Regulation   Reduce negative emotions 
 
Antecedents   Restructuring the physical environment 
  Restructuring the social environment 
  Adding objects to the environment 
 
Identity/Self Belief  Framing/reframing 
  Verbal persuasion about capability 
  Focus on past success 
  Self-talk 
23 (92) 
19 (76) 
20 (80) 
24 (96) 
22 (88) 
17 (68) 
 
23 (92) 
21 (84) 
9 (36) 
 
3 (12) 
14 (56) 
10 (40) 
 
24 (96) 
5 (20) 
1 (4) 
 
25 (100) 
7 (28) 
7 (28) 
 
23 (92) 
 
11 (44) 
 
21 (84) 
13 (52) 
15 (60) 
 
25 (100) 
4 (16) 
 
12 (48) 
 
0 (0) 
0 (0) 
9 (36) 
 
6 (24) 
21 (84) 
2 (8) 
5 (20) 
a ADL = activities of daily living, b classified according to the Behaviour Change Techniques Taxonomy version 1 
(Michie 2014) 
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Supplementary Table 2. Missing data at follow up 
Variables Values*  Total obtained  
(N) 
Missing of obtained  
N (%) 
Total obtained  
(N) 
Missing of obtained  
N (%) 
Patient Reported Measures Values* 30 days 60 days 
iPOS (17 items) 
Lower scores = fewer symptoms  
0-68  44 1 (2) 39 3 (8) 
PASE (12 Items) 
Higher scores = more active 
0-400  44 0 39 0 
FACT L (34 items) 
Higher scores = higher QoL 
0-136  44 1 (2) 39 0 
FACT TOI (21 items) 
Higher score = higher QoL 
0-84 44 1 (2) 39 0 
SEMCD (6 items) 
Higher score = greater confidence 
0-10  44 0 39 1 (3) 
EQ-5D-5L (Index values) 
Lower score = higher QoL 
0-1 44 0 39 2 (4) 
EQ VAS Higher score = higher QoL 0-100 44 0 39 2 (4) 
CSRIa- Hospital based care Yes/no; number/information 44 6 (14) 39 7 (18) 
CSRI- Community based care Yes/no; number/duration/information 44 6(14) 39 4 (10) 
CSRI-Investigations Yes/no; number/duration/information 44 10 (23) 39 6 (15) 
CSRI- Personal Care Yes/no; number/duration/information 44 20 (45) 39 10 (26) 
CSRI-Equipment Yes/no; number/duration/information 44 3 (7) 39 2 (5) 
CSRI- Medication Yes/no; number/duration/information 44 3 (7) 39 5 (13) 
Trial Satisfaction (4 items) 0-4 44 1 (6) n/a n/a 
Treatment satisfaction (10 items) 9 items 0-3 
1 item 0-4 
15/25 expected 1 (6) n/a n/a 
 
IPOS =Integrated Palliative Care Outcome Scale; PASE= Physical Activity Scale for the Elderly; FACT-L/TOI/LCS = Functional Assessment of Cancer Therapy- Lung/trial 
outcome index/lung cancer subscale; SEMCD = Self-Efficacy Measure for Chronic Disease; FACIT-PS-TS = Functional Assessment of chronic illness therapy treatment/ 
patient satisfaction. CSRI = Client Services Receipt Inventory. aDomain data is recorded missing if contact and frequency items within the domain were missing 
 
